Last reviewed · How we verify
clozapine 100 mg
Clozapine 100 mg, marketed by Taipei Medical University WanFang Hospital, holds a niche position in the psychiatric market. The key composition patent expires in 2028, providing a period of exclusivity that supports market stability. The primary risk is the lack of revenue data, which limits the ability to assess financial performance and market impact.
At a glance
| Generic name | clozapine 100 mg |
|---|---|
| Also known as | Clozaril |
| Sponsor | Taipei Medical University WanFang Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Stratification and Treatment in Early Psychosis Study -ASSIST (PHASE3)
- HDAC Inhibitor Augmentation to Clozapine (EARLY_PHASE1)
- Bioequivalence Study in Patients With Schizophrenia by Using Clozaril 100 mg Tablet (Clozapine) and WID-CLZ18 (PHASE1)
- The Efficacy of L-Carnitine in the Management of Acute Clozapine Intoxication (PHASE2)
- A Study Comparing the Efficacy and Tolerability of Ziprasidone vs. Clozapine for the Treatment of Schizophrenia in Patients Who Continue to Have Symptoms on or Cannot Tolerate Other Antipsychotic Drugs (PHASE3)
- Adjunctive Minocycline in Clozapine Treated Schizophrenia Patients (NA)
- First Episode Schizophrenia and Cannabis-Related Disorder Study (NA)
- Minocycline Augmentation to Clozapine (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |